BACKGROUND: Although the safety of combination chemotherapy without primary tumor resection (PTR) in patients with stage IV colon cancer has been established, questions remain regarding a potential survival benefit with PTR. The objective of this study was to compare mortality rates in patients who had colon cancer with unresectable metastases who did and did not undergo PTR. METHODS: An observational cohort study was conducted among patients with unresectable metastatic colon cancer identified from the National Cancer Data Base (2003)(2004)(2005). Multivariate Cox regression analyses with and without propensity score weighting (PSW) were performed to compare survival outcomes. Instrumental variable analysis, using the annual hospital-level PTR rate as the instrument, was used to account for treatment selection bias. To account for survivor treatment bias, in situations in which patients might die soon after diagnosis from different reasons, a landmark method was used. RESULTS: In the total cohort, 8641 of 15,154 patients (57%) underwent PTR, and 73.8% of those procedures (4972 of 6735) were at landmark. PTR was associated with a significant reduction in mortality using Cox regression (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.44-0.47) or PSW (HR, 0.46; 95% CI, 0. 44-0.49). However, instrumental variable analysis revealed a much smaller effect (relative mortality rate, 0.91; 95% CI, 0.87-0.96). Although a smaller benefit was observed with the landmark method using Cox regression (HR, 0.6; 95% CI, 0.55-0.64) and PSW (HR, 0.59; 95% CI, 0.54-0.64), instrumental variable analysis revealed no survival benefit (relative mortality rate, 0.97; 95% CI, 0.87-1.06). CONCLUSIONS: Among patients with unresectable metastatic colon cancer, after adjustment for confounder effects, PTR was not associated with improved survival compared with systemic chemotherapy; therefore, routine noncurative PTR is not recommended.
INTRODUCTION
Colorectal cancer is the second leading cause of cancer-related death in the United States, 1 and approximately 20% of patients present with distant metastases at the time of diagnosis. 2 In patients with unresectable metastatic disease, the primary treatment is systemic chemotherapy, and primary tumor resection (PTR) is indicated for the treatment of primary tumor-related complications. In the United States, noncurative PTR is common in patients who have metastatic disease and is the first treatment modality in most patients who undergo surgical resection and receive chemotherapy. 3 However, there is still significant controversy regarding the role of PTR and its potential impact on the survival in of patients with stage IV colorectal cancer.
PTR in the setting of unresectable metastatic disease is currently recommended for patients who present with tumorrelated complications, such as bleeding, obstruction, or perforation, which may preclude their ability to receive systemic therapy. Systemic therapy can be well tolerated as initial therapy in asymptomatic patients who have metastatic colorectal cancer, and only approximately 16% develop subsequent primary tumor-related complications requiring intervention. 4 However, recently, there has been renewed interest in the potential associations between PTR and improved survival even among patients who have asymptomatic, intact primary tumors. [5] [6] [7] [8] [9] Secondary analyses of patients enrolled in a multicenter randomized trial of systemic chemotherapy for metastatic colorectal cancer have demonstrated improved survival associated with undergoing PTR before enrollment. 10, 11 Because of important, unaddressed potential biases in those retrospective analyses, the question of whether PTR improves oncologic outcomes remains unanswered.
With the potential to reduce unnecessary use of PTR in patients who have stage IV disease with asymptomatic, intact primary tumors, the current study was conducted to compare the effectiveness of PTR among patients who had colon cancer and unresectable metastases using nationwide, hospital-based cancer registry data with modern analytical techniques aimed at controlling the sources of bias that threaten the validity of prior studies.
MATERIALS AND METHODS

Data Source and Patient Identification
The National Cancer Data Base (NCDB) was used to identify the study cohort. The NCDB is a joint program between the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society that serves as a surveillance tool to assess patterns of care for patients with cancer. The NCDB collects and reports patient data on over 70% of cancers diagnosed from over 1500 CoC-accredited cancer programs in the United States.
Adult patients who had stage IV colon adenocarcinoma diagnosed between 2003 and 2005 were included, because the dates of definitive surgery and patients' comorbidity scores were not recorded in the NCDB for patients who were diagnosed before 2003, and complete survival data were only available for those diagnosed before 2006. Exclusions included patients who underwent tumor-directed surgery within 24 hours of diagnosis (considered to have undergone nonelective resection) and those who underwent surgery for cancer of other sites (eg, metastectomy). Patients were censored if their deaths were not observed (ie, if a patient was alive at last follow-up or was lost to follow-up).
Statistical Methods
Sequential analytic methods for bias adjustment were used to determine the rate of overall survival (OS) by PTR status. A multivariate Cox regression analysis stratified by receipt of systemic chemotherapy was performed initially. Propensity score weighting (PSW) and instrumental variable analyses, using the annual hospital-level PTR rate as the instrument, were performed to account for selection bias.
In studying diseases with high mortality, patients may die soon after diagnosis for different reasons, resulting in survivor treatment bias. 12 Patients who underwent PTR must have survived from the date of diagnosis to the date of surgery to be included in the group, whereas no such requirement was made for patients in the non-PTR group. To overcome this issue, we used the landmark method to correct for the bias inherent in the analysis of time-to-event outcomes. Specifically, the landmark cohort was limited to patients who had survived for at least 1 year after diagnosis. The 1-year landmark was selected because PTR would be expected to have little clinical impact for a patient who was unlikely to survive beyond 12 months. In general, patients who are expected to survive less than 1 year are considered poor operative candidates who would derive limited benefit from elective surgery. To ensure that our choice of landmark did not lead to additional bias, a priori-determined sensitivity analyses were perform using 3-month, 6-month, 9-month, and 15-month landmarks.
Standard risk-adjustment methods
Kaplan-Meier and multivariate Cox regression analyses were performed after the stratification of patients according to receipt of systemic chemotherapy to compare survival outcomes with and without PTR. Multivariate Cox regression analyses adjusting for age, sex, race, year of diagnosis, tumor histology, tumor grade, tumor location, receipt of chemotherapy, insurance status, median income quartile, proportion without a high school degree by residence zip code, population density of residence, facility location, facility type, and comorbidity score were performed. Missing data were labeled as unknown. Regression analyses was performed with and without PSW to estimate the treatment effect while accounting for covariates that predict treatment administration. 13 A propensity model was developed to estimate an individual patient's probability of undergoing PTR (denoted as p). All covariates that affected both treatment assignment and outcome were included in the propensity score model. patients who underwent PTR and 1/(1 2 p) for patients who did not to estimate the treatment effect on OS. To ensure stable weighting, we incorporated the proportions of patients who did and did not undergo PTR into the weight.
Instrumental variable analysis
Instrumental variable analysis is 1 established approach in observational studies to control for hidden variables. 15 In determining the instrument, we considered the 2 key assumptions: 1) it is highly correlated with the treatment, and 2) it does not independently affect the outcome. The proportion of patients undergoing PTR at the treating hospital was used as the instrument; therefore, patients who received treatment at the same hospital and those who were treated at different hospitals with similar PTR rates would share the same hospital-level PTR rate. Instrumental variable models measure the treatment effect on mortality at 1 time point on an absolute scale (the effect is estimated using 2-stage least squares regression). Linear regression was used first to predict the treatment (PTR, yes vs no) as a function of instrument and other covariates. The obtained predicted treatment was then used to estimate the adjusted mortality difference in year 3 after diagnosis. The relative mortality rate (RMR) was calculated as 1 1 D/m nosurgery , where D is the instrument-adjusted absolute mortality difference, and m nosurgery is the KaplanMeier mortality rate among patients who did not undergo PTR. The obtained RMR was then compared with the hazard ratio (HR) derived from the multivariate Cox regression model. Instrument validation is described below (see Results).
These results are reported after publication of the Strengthening the Reporting of Observational Studies in Epidemiology statement. 16 All statistical analyses were performed using the Stata MP software package (version 11.2; Stata Corporation, College Station, Tex), with and the level of significance used was of P 5 .05.
RESULTS
Patient Characteristics
In total, 15,154 patients met the inclusion criteria, and 6735 of those patients were eligible for the 1-year landmark analysis subgroup (Supporting Table 1 ; see online supporting information). PTR was performed in 57% (n 5 8641) of the total patient cohort and in 73.8% (n 5 4972) of the landmark cohort. Thirty-day mortality was observed in 4.9% (n 5 755) of the entire cohort. Patients' demographics, socioeconomic indicators, and types and locations of the treating facility were similar between those who did and did not undergo PTR both in the total cohort and in the landmark cohort. In the landmark cohort, patients who underwent PTR (vs no PTR) were more likely to have low histologic grade (71.3%; P < .001). Baseline characteristics comparing patients based on 12-month OS are detailed in Table 1 .
In the landmark cohort, the median follow-up was 6.4 years (interquartile range [IQR], 5.50-7.24 years). The median time to PTR was 13 days (IQR, 5-24 days). The median time to chemotherapy was 28 days (IQR, 16-47 days) in those who did not undergo PTR and 54 days (IQR, 38-74 days) in those who did undergo PTR. Among the patients who received chemotherapy in addition to PTR, 94.3% received chemotherapy after surgery, and only 5.6% received chemotherapy before surgery. Approximately 25% of patients did not receive any systemic chemotherapy, and PTR was the only tumor-directed therapy (n 5 1143; 23%). The majority of surgical resections were performed within 30 days of diagnosis (n 5 4115; 82.3%).
Treatment Effect
Standard risk adjustment and propensity score analyses
On unadjusted analysis, PTR (vs no PTR) was associated with a 10.87-month increase in median OS for the total patient cohort (14.78 vs 3.91 months) and a 10-month increase among those who received systemic chemotherapy (n 5 8342; 20.34 vs 9.95 months) (Fig. 1) . PTR was associated with an approximately 55% relative reduction in mortality on multivariate Cox regression analysis (HR, 0.45; 95% confidence interval [CI], 0.43-0.47) and PSW (HR, 0.46; 95% CI, 0.43-0.48). Performing both adjusted and unadjusted analyses and stratification to include only those who received chemotherapy did not significantly alter these results (Table 2) .
Instrumental variable analyses
The first-stage F-statistic derived from the 2-stage leastsquares regression was used to test the first assumption that the instrument was highly correlated with treatment. The obtained F-statistic of 1372.31 indicates that the proposed instrument is a sufficiently strong predictor that patients will undergo PTR. As a general rule, an instrument with an F-statistic > 10 is considered to be strong. To evaluate the second assumption that the instrument was unrelated to the characteristics of the patients, we analyzed the distribution of observed variables across levels of the instrument (Supporting Table 1 ; see online supporting information). The mean hospital-level PTR rate within 30 days of diagnosis Original Article By using instrumental variable analysis, the PTRassociated survival benefit was attenuated, with an adjusted absolute mortality difference of 0.08 at 3 years, (95% CI, 0.03-0.12). This corresponds to an adjusted RMR of 0.91 (95% CI, 0.86-0.95). Stratification by systemic chemotherapy further attenuated the observed benefit (Table 2) . Finally, although the likelihood of undergoing PTR at a given institution could have been influenced by patient referral, in which patients who received treatment at certain hospitals were more likely to undergo PTR (ie, referral bias), the PTR associated survival benefit was similar across the different quintiles of PTR rate.
Landmark analyses
When evaluating early mortality, we observed that the majority of deaths occurred within the first 90 days after diagnosis; this was especially true for the no-PTR group (Fig. 1) . Patients who did not survive to the landmark time were less likely to receive any treatment modality (62% received no chemotherapy, and 56% underwent no resection vs 23% and 26%, respectively, in the landmark subgroup), thus indicating survivor treatment bias (Table  1 ). This significant difference was no longer observed when the landmark method was used. When the 1-year landmark was used, a survival benefit still was observed with PTR on standard multivariate Cox regression (HR, 0.60; 95% CI, 0.55-0.64) and PSW (HR, 0.59; 95% CI, 0.54-0.64) ( Table 2 ). This benefit was abrogated when instrumental variable analysis was used (adjusted RMR, 0.97; 95% CI, 0.87-1.06) (Fig. 2) .
Sensitivity analyses were performed to evaluate the impact of landmark threshold on the instrumental variable-adjusted mortality 3 years after diagnosis (Fig. 3) . The PTR-associated survival benefit became insignificant when the instrumental variable method was applied at the 3-month landmark (adjusted RMR, 0.95; 95% CI, 0.89-1.01).
DISCUSSION
The decision to undergo PTR among patients who present with primary-intact stage IV colon cancer is one that is commonly faced by patients and their physicians. Data regarding the survival impact of PTR in this setting are conflicting, and strong provider biases exist regarding the role of up-front PTR or selective resection when symptoms develop. 17 By using standard statistical riskadjustment methods, which inadequately account for confounder effects, PTR appeared to be associated with a significant reduction in mortality. However, instrumental variable analysis to control for treatment selection and survivor time bias at the 1-year landmark demonstrated that PTR was not associated with a survival benefit over systemic chemotherapy. Stratification by receipt of systemic chemotherapy did not alter the results. Thus, we demonstrate that the routine use of PTR in patients with stage IV colon cancer and unresectable metastatic disease does not improve survival.
There is significant disagreement in the literature regarding the impact of PTR on survival. In the United States, >50% of patients with this pattern of advanced colorectal cancer undergo PTR, and there are many providers Abbreviations: CI, confidence interval; IPTW, propensity score inverse probability of treatment weighting. a Analyses were adjusted for the following variables based on their availability in the National Cancer Data Base and their clinical significance: age at diagnosis, sex, race, year of diagnosis, tumor histology, tumor grade, tumor location, chemotherapy, insurance status, median income quartile, proportion without a high school degree by zip code, population density of residence by zip code, facility location, facility type, and comorbidity score.
who still advocate for its routine use. 3 In part, this may be because much of the current literature suggests that palliative PTR may offer a significant survival benefit. [5] [6] [7] 10 In a secondary analysis of 294 patients with nonresectable colorectal cancer metastases who were enrolled in a phase 3 randomized, controlled, systemic chemotherapy trial, patients who underwent PTR before enrollment had higher rates of OS than those who did not undergo PTR. 11 This effect was independent of the site of the primary (colon vs rectum); however, the majority of those patients had a single metastasis confined to the liver. Similarly, in a meta-analysis 7 using survival data from 21 retrospective studies with a total of 44,226 patients who had metastatic colorectal cancer, PTR compared with chemotherapy alone was associated with a lower mortality rate. However, all but 2 of the studies in that analysis were single-center studies, and the other 2 studies used administrative databases with limited specific information regarding how patients were selected for surgical intervention.
Those studies are highly subject to treatment selection bias, and caution is required when suggesting a causal relation between PTR and improved survival. Patients with significant noncancer comorbidities who are at greater risk for all-cause mortality are less likely to undergo PTR. Those patients who do undergo PTR have better performance status and are more likely to receive palliative systemic therapy than patients who do not undergo PTR. 6 Patients with greater metastatic tumor burden are subject to greater cancer-related mortality but may be less likely to undergo PTR. Finally, failure to exclude patients who undergo resection of the both the primary tumor and metastases with curative intent can bias the results in favor of PTR.
When estimating a survival benefit using observational data, if the treatment assignment is not randomized or the indication for assignment is not well characterized, then the analytic method can critically impact the results. Propensity score analysis can reduce the effect of selection bias by accounting for the conditional probability of treatment based on all known factors available for inclusion in the propensity model. However, as with standard riskadjustment methods, propensity score analyses are subject to the limitation of unmeasured factors that contribute to treatment selection bias. Instrumental variable analysis is an alternate analytic method for causal inference that can control for known and unknown confounders in observational studies and is particularly useful when randomized controlled trials are unavailable or cannot be performed. 13, 18 An additional major bias influencing survival outcome determination in diseases with high mortality is the length of survival itself and how it influences patients' chances of being assigned to 1 treatment or another: socalled survivor treatment bias. 12 Patients with a poor survival prognosis who would have died soon after diagnosis would not have had the opportunity to undergo surgical resection, thereby guaranteeing poorer survival for the nonsurgical group. One effective approach to overcome this problem is the landmark method. 19 Previous studies have been limited by incomplete adjustment for both treatment selection and survivor time bias. In the current study, we combined several techniques to account for both types of bias. Having done so, we could no longer demonstrate a survival benefit of PTR. This study has several limitations. Like other observational studies that have used administrative databases, the intent of treatment was difficult to evaluate (eg, patients receiving chemotherapy with the intent to undergo resection in the future vs those receiving chemotherapy with purely palliative intent). Although the focus this study was on the effect of PTR in the palliative setting and excluded from analysis those patients who underwent curative-intent PTR with metastectomy, removing patients with a good prognosis from the PTR group while retaining those who had a poor response to chemotherapy could negatively impact survival in the PTR arm. We did note, however, that the time to systemic chemotherapy was nearly doubled among the patients who underwent PTR and that 1 in 4 patients who underwent PTR never received systemic chemotherapy, indicating the potential adverse impact of PTR on the ability to receive chemotherapy. Similarly, resections performed to palliate symptoms could not be distinguished from those that were performed in asymptomatic patients. To address this issue, patients who underwent tumor-directed surgery within 24 hours of diagnosis were excluded from the analysis (because their resections were considered nonelective). To ensure that our choice of a 24-hour cutoff did not bias the results, additional sensitivity analyses were perform using 48 and 72 hours, and the results were similar (data not shown). Furthermore, patients who were initially asymptomatic and developed symptoms over time could not be definitively identified. In fact, it is likely that PTR is beneficial in initially asymptomatic patients who are at high risk for developing tumor-related complications, such as those with long-segment circumferential tumors. If this group was represented by the 14% who underwent resection more than 30 days after diagnosis, then our findings are comparable to the 16% of such patients reported in literature. 4 Although the NCDB reports outcomes on over 70% of patients with new cancer diagnoses in the United States, outcomes for patients treated in non-CoC-accredited hospitals may be different, and it is possible that our results may not reflect treatment at non-CoC-accredited hospitals. However, the PTR rate in our study cohort was similar to that reported in studies that used different databases, suggesting that our findings can be generalized. 3 In addition, although instrumental variable analysis is a widely accepted technique to account for hidden bias, there remains potential for instrument-outcome confounding, such as receipt of other treatments also associated with our instrument and the outcome. 20 One example is the possibility of greater early mortality in facilities with high PTR use; however, the impact of this potential confounder was minimized by landmark analysis, because facility-associated mortality tends to be associated with earlier deaths. Finally, survival has significantly improved in this patient population in the recent era, and the potential for PTR after initial systemic chemotherapy should continue to be evaluated.
In contrast to what has been suggested previously in large registry studies, the current findings highlight that, in routine practice with unselected patients, PTR does not provide a survival advantage for patients who have colon cancer with unresectable metastases, but it may delay the time to initiation of systemic therapy. These results also demonstrate that the previously observed treatmentrelated benefits are subject to overestimation because of bias that is not accounted for using standard analytical methods. Although there is potential that a subgroup of patients may benefit from PTR in addition to systemic chemotherapy, the current study demonstrates that, in routine use, PTR does not improve survival. Ongoing randomized controlled trials (eg, the Dutch Colorectal Cancer Group CAIRO4 trial) will add to the literature in this field; and ongoing studies may provide additional insight, including the French Digestive Oncology Federation GRECCOR8 trial and the German Synchronous trial. Accrual to randomized investigations should be encouraged so that we can get closer to definitive answers. The current results provide new perspective into the impact of PTR to guide decision making in the real world.
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